Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Contemporary Management of Anaplastic Thyroid Cancer
Wilson Alobuia, Andrea Gillis, Electron Kebebew
Current Treatment Options in Oncology (2020) Vol. 21, Iss. 10
Closed Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

A pan-cancer analysis of the oncogenic role of secreted phosphoprotein 1 (SPP1) in human cancers
Yafei Liu, Guanchao Ye, Bo Dong, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 6, pp. 279-279
Open Access | Times Cited: 31
Multimodal and multiscale optical imaging of nanomedicine delivery across the blood-brain barrier upon sonopermeation
Jan‐Niklas May, Susanne K. Golombek, Maike Baues, et al.
Theranostics (2020) Vol. 10, Iss. 4, pp. 1948-1959
Open Access | Times Cited: 38
Update on current diagnosis and management of anaplastic thyroid carcinoma
T. Pavlidis, I. Galanis, T. Pavlidis
World Journal of Clinical Oncology (2023) Vol. 14, Iss. 12, pp. 570-583
Open Access | Times Cited: 12
Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy
Jingjing Wang, Jie Tan, Bian Wu, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 11
Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment Strategy
Janice Pakkianathan, Celina R. Yamauchi, Luiza Barseghyan, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 9, pp. 2898-2898
Open Access
Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo
Le Xiong, Xiao-Min Lin, Jun‐Hua Nie, et al.
Nanotheranostics (2021) Vol. 5, Iss. 2, pp. 143-154
Open Access | Times Cited: 27
GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma
Haoji Gao, Weige Wang, Qinyu Li
Cancer Biology & Therapy (2022) Vol. 23, Iss. 1, pp. 369-377
Open Access | Times Cited: 17
Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs
Alessandro Prete, Antonio Matrone, Carla Gambale, et al.
Cancers (2021) Vol. 13, Iss. 13, pp. 3200-3200
Open Access | Times Cited: 23
Modulation of EZH2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid Cancer
Diego Claro de Mello, Kelly Cristina Saito, Marcella Maringolo Cristovão, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7872-7872
Open Access | Times Cited: 8
Pan-Genomic Sequencing Reveals Actionable CDKN2A/2B Deletions and Kataegis in Anaplastic Thyroid Carcinoma
Adam Stenman, Minjun Yang, Johan O. Paulsson, et al.
Cancers (2021) Vol. 13, Iss. 24, pp. 6340-6340
Open Access | Times Cited: 20
Ultrasound-Guided Radiofrequency Ablation Versus Surgical Resection for the Treatment of T1bN0M0 Papillary Thyroid Carcinoma in Different Age Groups
Hongying He, Rilige Wu, Jiahang Zhao, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 16
Role of m6A RNA Methylation in Thyroid Cancer Cell Lines
Lorenzo Allegri, Federica Baldan, Elisabetta Molteni, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11516-11516
Open Access | Times Cited: 11
Exploring the Meaning of Spirituality and Spiritual Care with Help From Viktor Frankl
Katherine Britt, Gayle J. Acton
Journal of Holistic Nursing (2021) Vol. 40, Iss. 1, pp. 46-55
Closed Access | Times Cited: 15
GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation
Elisabetta Molteni, Federica Baldan, Giuseppe Damante, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5993-5993
Open Access | Times Cited: 6
Efficacy and safety of ultrasound-guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma in patients aged 55 years or older: a retrospective study
Hongying He, Qing Song, Yu Lan, et al.
International Journal of Hyperthermia (2021) Vol. 38, Iss. 1, pp. 604-610
Open Access | Times Cited: 14
The Knockdown of Nrf2 Suppressed Tumor Growth and Increased the Sensitivity to Lenvatinib in Anaplastic Thyroid Cancer
Zhongqin Gong, Lingbin Xue, Minghui Wei, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 12
The emerging role of transcription factor FOXP3 in thyroid cancer
Zhongqin Gong, Jia Hao, Lingbin Xue, et al.
Reviews in Endocrine and Metabolic Disorders (2021) Vol. 23, Iss. 3, pp. 421-429
Closed Access | Times Cited: 9
Effects of Dihydrotanshinone I on Proliferation and Invasiveness of Paclitaxel-Resistant Anaplastic Thyroid Cancer Cells
Lorenzo Allegri, Francesca Capriglione, Valentina Maggisano, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8083-8083
Open Access | Times Cited: 8
Modulatory role of miRNAs in thyroid and breast cancer progression and insights into their therapeutic manipulation
Rubai Ahmed, Sovan Samanta, Jhimli Banerjee, et al.
Current Research in Pharmacology and Drug Discovery (2022) Vol. 3, pp. 100131-100131
Open Access | Times Cited: 6
PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer
Wei Zhu, Bin Xie
Cancer Biology & Therapy (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 3
TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice
Noelle E. Gillis, Lauren Cozzens, Emily R Wilson, et al.
Endocrinology (2023) Vol. 164, Iss. 10
Open Access | Times Cited: 3
Pathologic complete response after neoadjuvant v-Raf murine sarcoma viral oncogene homolog B (BRAF) inhibition combined with immunotherapy therapy for anaplastic thyroid carcinoma: a case report and literature review
Yuntao Song, Yanhua Bai, Jiaxin Wang, et al.
Endocrine Journal (2022) Vol. 70, Iss. 2, pp. 223-228
Open Access | Times Cited: 5
Aberrant DNA repair as a potential contributor for the clonal evolution in subsets of anaplastic thyroid carcinomas arising through dedifferentiation: implications for future therapeutic algorithms?
C. Christofer Juhlin
Cancer Drug Resistance (2020)
Open Access | Times Cited: 4
Nomogram prediction for the involution of the ablation zone after radiofrequency ablation treatment in patients with low-risk papillary thyroid carcinoma
Hongying He, Yan Zhang, Qing Song, et al.
International Journal of Hyperthermia (2021) Vol. 38, Iss. 1, pp. 1133-1139
Open Access | Times Cited: 4
Laryngotracheal Resection After B-Raf Proto-oncogene Inhibition for Anaplastic Thyroid Carcinoma
Johnathan R. Kent, Philip G. Erwin, Daniel J. Haraf, et al.
The Annals of Thoracic Surgery (2022) Vol. 115, Iss. 5, pp. e117-e120
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top